Abstract:Carcinoma of unknown primary (CUP) is a type of metastatic cancer, the primary tumor site of which cannot be identified. CUP occupies approximately 5% of cancer incidences in the United States with usually unfavorable prognosis, making it a big threat to public health. Traditional methods to identify the tissue-of-origin (TOO) of CUP like immunohistochemistry can only deal with around 20% CUP patients. In recent years, more and more studies suggest that it is promising to solve the problem by integrating machine learning techniques with big biomedical data involving multiple types of biomarkers including epigenetic, genetic, and gene expression profiles, such as DNA methylation. Different biomarkers play different roles in cancer research; for example, genomic mutations in a patient’s tumor could lead to specific anticancer drugs for treatment; DNA methylation and copy number variation could reveal tumor tissue of origin and molecular classification. However, there is no systematic comparison on which biomarker is better at identifying the cancer type and site of origin. In addition, it might also be possible to further improve the inference accuracy by integrating multiple types of biomarkers. In this study, we used primary tumor data rather than metastatic tumor data. Although the use of primary tumors may lead to some biases in our classification model, their tumor-of-origins are known. In addition, previous studies have suggested that the CUP prediction model built from primary tumors could efficiently predict TOO of metastatic cancers ( Lal et al., 2013 ; Brachtel et al., 2016 ). We systematically compared the performances of three types of biomarkers including DNA methylation, gene expression profile, and somatic mutation as well as their combinations in inferring the TOO of CUP patients. First, we downloaded the gene expression profile, somatic mutation and DNA methylation data of 7,224 tumor samples across 21 common cancer types from the cancer genome atlas (TCGA) and generated seven different feature matrices through various combinations. Second, we performed feature selection by the Pearson correlation method. The selected features for each matrix were used to build up an XGBoost multi-label classification model to infer cancer TOO, an algorithm proven to be effective in a few previous studies. The performance of each biomarker and combination was compared by the 10-fold cross-validation process. Our results showed that the TOO tracing accuracy using gene expression profile was the highest, followed by DNA methylation, while somatic mutation performed the worst. Meanwhile, we found that simply combining multiple biomarkers does not have much effect in improving prediction accuracy.

Predicting Tissue of Origin from Bulk Tumor Gene Expression using a Pre-trained Transformer Model

A Transformer-Based Model for Preoperative Early Recurrence Prediction of Hepatocellular Carcinoma with Muti-modality MRI

A Self-Supervised Transformer-Based Model for Early Recurrence Prediction of HCC with Multimodal MRI

A Transformer-Based Approach to Survival Outcome Prediction

Tumor origin identification through machine learning and gene expression profiling.

Predicting Cancer Tissue-of-Origin by a Machine Learning Method Using DNA Somatic Mutation Data.

A Machine Learning Approach for Tracing Tumor Original Sites With Gene Expression Profiles

TOOme: A Novel Computational Framework to Infer Cancer Tissue-of-Origin by Integrating Both Gene Mutation and Expression

Abstract 6191: Simultaneous prediction of tumor microenvironment biomarkers from pathology slides using multi-task deep regression

Detection and Localization of Solid Tumors Utilizing the Cancer-Type-Specific Mutational Signatures

Tracing unknown tumor origins with a biological-pathway-based transformer model

TULIP: An RNA-seq-based Primary Tumor Type Prediction Tool Using Convolutional Neural Networks

A Neural Network Framework for Predicting the Tissue-of-Origin of 15 Common Cancer Types Based on RNA-Seq Data.

BulkRNABert: Cancer prognosis from bulk RNA-seq based language models

Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Harnessing TME depicted by histological images to improve cancer prognosis through a deep learning system

A Robust Personalized Classification Method for Breast Cancer Metastasis Prediction

35P Exploring a Machine Learning Approach to Predict Tumour Type from Targeted Panel DNA Sequence Data

Deep Discriminative Fine-Tuning for Cancer Type Classification

Convolutional neural network models for cancer type prediction based on gene expression